Haleon Stock - Analyst consensus and sector context on a quiet news day
19.06.2026 - 22:49:46 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:48 UTC. Details in the imprint.
Haleon (GB00BMX86B70) enters the weekend without new corporate announcements, so the focus for investors shifts to analyst consensus and the wider consumer-health sector landscape. With no fresh IR or regulatory filings reported by leading financial wires today, the stock trades mainly on fundamentals and positioning.
All news and key data on Haleon stock
Additional disclosures, historical releases and key documents on Haleon can be found in the dedicated topic area and on the company's investor-relations pages.
What analysts currently expect
On a consensus basis, Haleon is generally rated in the middle of the range, with many brokers still recommending to increase positions rather than to exit entirely, according to data compiled by MarketScreener as of mid-June 2026.
The same dataset points to a medium-term operating-profit growth ambition in the high single-digit percentage range, which the company has outlined for its consumer-health portfolio.
How Haleon compares with peers
Within the global consumer-health and over-the-counter medicines segment, Haleon competes with diversified giants such as Johnson & Johnson's Kenvue spin-off and Sanofi's consumer brands, which offers investors several alternative ways to access similar demand trends.
All told, Haleon's pure-play profile in consumer health sets it apart from some larger, more diversified pharma and consumer groups, where over-the-counter products account for a smaller share of overall earnings.
What the company sells
Haleon generates most of its revenue from over-the-counter consumer-health brands, including oral-care products such as Sensodyne toothpaste, pain-relief medicines like Panadol, and respiratory brands including Otrivin, alongside vitamins, minerals and supplements.
Where the stock trades today
The shares of Haleon (GB00BMX86B70) trade on the London Stock Exchange at around 336.90p as of 06/19/2026, 09:07 BST, based on recent quote data.
Key facts on Haleon stock
- Company: Haleon plc
- ISIN: GB00BMX86B70
- WKN: A3DTQZ
- Ticker: HLN
- Venue: London Stock Exchange
- Price (as of 06/19/2026, 09:07 BST): 336.90p GBP
- Market cap: approximately GBP 30 billion (as of 06/19/2026)
- Sector / Industry: Health Care - Consumer Health / OTC Medicines
- Index membership: FTSE 100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
